IPHA Stock Risk & Deep Value Analysis
Innate Pharma SA
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About IPHA Stock
We analyzed Innate Pharma SA using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran IPHA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
IPHA Risk Analysis & Red Flags
What Could Go Wrong
The company is facing a critical cash crunch with runway only until end-Q3 2026 and negative shareholders' equity, coupled with a 'going concern' warning. Failure to secure substantial financing in the coming months, likely through highly dilutive share offerings, or negative results from the upcoming Monalizumab Phase 3 trial, would lead to potential bankruptcy, delisting, or severe value destruction.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
High
Red Flags
- ⚠
Explicit 'going concern' doubt flagged in FY2025 results
- ⚠
Cash runway only to end-Q3 2026 (€44.8M as of Dec 31, 2025)
- ⚠
Negative shareholders’ equity of -€21.7 million
- ⚠
55% year-over-year revenue decline in FY2025
- ⚠
Past share dilution (increase in weighted average shares outstanding)
Upcoming Risk Events
- 📅
Failure to secure adequate financing by end-Q3 2026
- 📅
Negative or inconclusive results from PACIFIC-9 monalizumab Phase 3 trial
- 📅
Significant dilution from future capital raises
- 📅
Further deterioration of cash position and burn rate
When to Reconsider
- 🚪
No financing secured or announced by end of Q2 2026
- 🚪
Negative or significantly delayed Monalizumab Phase 3 data readout
- 🚪
Announcement of highly dilutive capital raise with poor terms or insufficient funds
- 🚪
Further significant decline in cash balance without offsetting revenue/financing
Unlock IPHA Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Innate Pharma SA (IPHA) Do?
Market Cap
$196.56M
Sector
Healthcare
Industry
Biotechnology
Employees
174
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Visit Innate Pharma SA WebsiteInvestment Thesis
Innate Pharma is a highly speculative, binary investment banking on its promising NK cell-targeting oncology pipeline, particularly monalizumab (partnered with AstraZeneca) and lacutamab. While facing severe immediate financial challenges ('going concern' and limited cash runway), successful positive Phase 3 data for monalizumab in H2 2026, coupled with securing substantial financing, could unlock multi-bagger returns from its currently distressed market capitalization. This is a bet on pipeline potential overcoming financial distress.
Is IPHA Stock Undervalued?
Unlock the full AI analysis for IPHA
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
IPHA Price Targets & Strategy
12-Month Target
$7.00
Bull Case
$13.00
Bear Case
$0.10
Valuation Basis
Speculative valuation based on successful Monalizumab Phase 3 readout and securing of substantial, non-crippling financing, leading to an estimated $500M+ market capitalization.
Entry Strategy
Extremely speculative. Only consider accumulating a small position upon confirmation of successful financing or positive Monalizumab Phase 3 data, given current 'going concern' risk. No clear technical support levels given current volatility.
Exit Strategy
Take profit on significant positive news (e.g., successful financing, positive Monalizumab data). Implement a tight stop-loss below $1.00 if no financing is secured by Q3 2026 or if clinical data is negative.
Portfolio Allocation
1-3% for aggressive, high-risk tolerance portfolios only.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does IPHA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable, but heavily reliant on financial stability to realize its potential. At risk of erosion if funding fails.
Moat Sources
2 Identified
The moat's durability is highly contingent on successful clinical trial outcomes and the company's ability to secure long-term financing. Without successful trials and funding, the intellectual property and partnerships may not translate into a sustainable competitive advantage.
Moat Erosion Risks
- •Failure of key clinical trials (e.g., Monalizumab Phase 3)
- •Inability to secure crucial financing, leading to asset sales or bankruptcy
- •Emergence of superior or more advanced NK cell-targeting therapies from competitors
IPHA Competitive Moat Analysis
Sign up to see competitive advantages
IPHA Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral, likely leaning bearish due to financial distress and lack of immediate positive catalysts.
Institutional Sentiment
Neutral/Negative, as indicated by no analyst coverage or recent institutional ownership data, suggesting minimal interest amidst high risk.
Insider Activity (Form 4)
No Form 4 filings or insider buys/sells reported in the last 90 days (Jan 11-Apr 10, 2026).
Options Flow
Normal options activity; no specific data indicating unusual institutional positioning available.
Earnings Intelligence
Next Earnings
Estimated mid-2026 for H1 2026 results
Surprise Probability
High (any positive update on financing or cash burn could be a significant positive surprise given the current situation)
Historical Earnings Pattern
No specific historical pattern is available; however, given the financial state, earnings reports are likely to be highly volatile and primarily driven by updates on liquidity and pipeline progress.
Key Metrics to Watch
Competitive Position
Top Competitor
Kyowa Kirin (with mogamulizumab in CTCL)
Market Share Trend
Not applicable yet for its pipeline drugs, as they are pre-commercial or in late-stage development.
Valuation vs Peers
Not directly comparable due to its distressed financial state. Its extremely low market capitalization ($0.11B) reflects severe risk rather than inherent undervaluation of its pipeline assets.
Competitive Advantages
- •Proprietary expertise and IP in NK cell-targeting immunotherapies
- •Strategic partnership with AstraZeneca for global development of monalizumab
- •Diversified oncology pipeline addressing multiple indications
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive IPHA Stock Higher?
Near-Term (0-6 months)
- •Successful securing of substantial financing (expected H1-H2 2026)
- •Completion of workforce reduction/restructuring (H1 2026)
- •Q1 2026 earnings report (estimated mid-2026, focus on cash burn and financing updates)
Medium-Term (6-18 months)
- •PACIFIC-9 Phase 3 monalizumab data readout (H2 2026)
- •TELLOMAK-3 Phase 3 lacutamab trial initiation (H2 2026, pending financing)
Long-Term (18+ months)
- •Monalizumab regulatory approval and commercialization (post-2026)
- •Lacutamab regulatory approval and commercialization (post-2026)
- •Advancement of IPH4502 and other preclinical assets
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for IPHA?
- ✓
Announcement of successful capital raise and its terms
- ✓
Official release of positive PACIFIC-9 (monalizumab) Phase 3 data
- ✓
Significant reduction in quarterly cash burn rate
Bull Case Analysis
See what could go right with Premium
Competing with IPHA
See how Innate Pharma SA compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Innate Pharma SA IPHA | $196.6M | 4.5 | — | $14.8M | 0.0% | -55.2% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Innate Pharma SA Makes Money
Innate Pharma is a French biopharmaceutical company that operates as an oncology-focused biotechnology firm. It specializes in discovering, developing, and commercializing novel therapeutic antibodies that leverage the body's natural killer (NK) cells to fight cancer. The company generates revenue primarily through collaboration and licensing agreements with larger pharmaceutical partners, who often take on later-stage clinical development and commercialization in exchange for upfront payments, milestone payments based on development progress, and future royalties on sales of approved drugs. They also receive governmental funding for research.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Innate Pharma SA (IPHA)?
As of April 10, 2026, Innate Pharma SA has a DVR Score of 4.5 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Innate Pharma SA?
Innate Pharma SA's market capitalization is approximately $196.6M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Innate Pharma SA use?
IPHA is the ticker symbol for Innate Pharma SA. The company trades on the NMS.
What is the risk level for IPHA stock?
Our analysis rates Innate Pharma SA's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Innate Pharma SA's revenue growing?
Innate Pharma SA has reported revenue growth of -55.2%. Revenue has been declining, which warrants closer examination.
Is IPHA stock profitable?
Innate Pharma SA has a profit margin of 0.0%. The company is currently unprofitable.
How often is the IPHA DVR analysis updated?
Our AI-powered analysis of Innate Pharma SA is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 10, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for IPHA (Innate Pharma SA) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.